Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
TuHURA Biosciences, Inc.
4SC AG
EMD Serono
Immunomic Therapeutics, Inc.
OncoSec Medical Incorporated
Fate Therapeutics
Incyte Corporation
AbbVie
AbbVie
Incyte Corporation
Novartis
Incyte Corporation
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
ImmunoGen, Inc.